XL-647
XL-647 is an orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. It binds to and inhibits several receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4).
Product Specifications
Shipping Conditions
gel pack
Storage Conditions
-20°C
Shelf Life
36 months
More Discoveries
Explore Other Products
Browse additional items from our catalog